Vaccine Safety & Pharmacovigilance Publications 

de Oliveira PMN, Hartmann K, Bhamare C, Lucchesi MBB; DCVMN PV Working Group. Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries. Vaccine 2025, Feb 27; 48:126727

ShamaeiZadeh PA, Jaimes CV, Knoll MD, Espié E, Chandler RE. Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally. Vaccine X 2024, Apr 10; 18:100485

Chandler RE, Balakrishnan MR, Brasseur D, Bryan P, Espié E, Hartmann K, et al. Collaboration within the global vaccine safety surveillance ecosystem during the COVID-19 pandemic: lessons learnt and key recommendations from the COVAX Vaccine Safety Working Group. BMJ Global Health 2024: 9:e014544

Levitan B, Hadler SC, Hurst W, et al. The Brighton collaboration standardized module for vaccine benefit-risk assessment. Vaccine 2024, Feb 6; 42(4):972-986

Black SB, Chandler RE, Edwards KM, Sturkenboom MCJM. Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future. Vaccine 2023, Jun 7; 41(25):3790-3795

Top KA, Chen RT, Levy O, et al. Advancing the Science of Vaccine Safety During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond: Launching an International Network of Special Immunization Services. Clinical Infectious Diseases 2022, Aug 15; 75(Suppl 1):S11-S17

Hartmann K, Pagliusi S, Precioso A. Landscape analysis of pharmacovigilance and related practices among 34 vaccine manufacturers from emerging countries. Vaccine 2020, Jul 22; 38(34):5490-5497